Novel euglycemic and hypolipidemic agents

Journal of Medicinal Chemistry

Volumn 41, Issue 10, 1998, Pages 1619-1630

  Lohray, Braj B ^a   Bhushan, Vidya ^a   Rao, Bheema P ^a   Madhavan, Gurram R ^a   Murali, Nagabelli ^a   Rao, Krowidi N ^a   Reddy, Ananth K ^a   Rajesh, Bagepalli M ^a   Reddy, Pamulapati G ^a   Chakrabarti, Ranjan ^a   Vikramadithyan, Reeba K ^a   Rajagopalan, Ramanujam ^a   Mamidi, Rao N V S ^a   Jajoo, Hemant K ^a   Subramaniam, Swaminathan ^a  

^a DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [4 [2 (1 INDOLYL)ETHOXY]BENZYL] 2,4 THIAZOLIDINEDIONE; ANTILIPEMIC AGENT; ENGLITAZONE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYDROGENATION; HYPERGLYCEMIA; HYPOLIPEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; DRUG EVALUATION, PRECLINICAL; HYPOGLYCEMIC AGENTS; INDOLES; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 15144348713     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970444e     Document Type: Article

References (98)

1. (a) DeFronzo, R. A. The triumvirate: β cell, muscle, liver a collusion responsible for NIDDM. Diabetes 1988, 37, 667.
2. (b) Turner, R. C.; Mathews, D. R.; Clark, A.; O'Rahilly, S.; Rudenski, A. S.; Levy, J. Clin. Endrocrinol Metab. 1988, 2, 327.
3. (c) Reaven, G. M. Diabetes 1988, 37, 1595-1607.
4. (a) Feldt-Rasmussen, B.; Mathiesen, E.; Deckert, T. Effect of Two Years of Strict Metabolic Control on Progression of Inapient Nephropathy in Insulin-Dependent Diabetes. Lancet 1986, 2, 1300-1304.
5. (b) Dahl-Jorgensen, K.; Brinchmann-Hansen, O.; Hanssen, K. F.; Ganes, T.; Kierulf, P.; Smeland, E.; Sandvik, L.; Aagenaes, O. Effect of Near-Normoglycemia for Two Years on Progression of Early Diabetic Retinopathy, Nephropathy, and Neuropathy; The Oslo Study. Br. Med. J. 1986, 293, 1195-1199.
6. (c) Pirart, J. Diabetes Mellitus and its Degenerative Complications, A Prospective Study of 4,400 Patients Observed between 1947 and 1973. Diabetes Care 1978, 1, 168-188, 252-263.
7. Jaspan, J. B. Monitoring and Controlling the Patient with Non-Insulin Dependent Diabetes Mellitus, Metabolism 1987, 36 (Suppl. 1), 22-27.
8. Gerich, J. E. Oral Hypoglycemic Agents. N. Engl. J. Med. 1989, 321, 1231-1245.
9. (a) Goldman, J. M. Oral Hypoglycemic Agents: an Update of Sulfonylureas. Drugs Today 1989, 25, 689-695.
10. (b) Kolterman, O. G.; Prince, M. J.; Olefsky, J. M. Insulin Resistance in Non- Insulin Dependent Diabetes Mellitus. Impact of sulfonylureas agents in vivo and in vitro. Am. J. Med. 1983, 74 (Suppl. 1A), 82-101.
11. (c) Bailey, C. J. Hypoglycemic and anti-hyperglycemic drugs for the control of diabetic. Proc. Nutr. Soc. 1991, 50, 619-630.
12. (a) Holman, R. R.; Turner, R. C. Oral Agents and Insulin in the treatment of Non-Insulin-Dependent Diabetes-Mellitus. In Text Book of Diabetes; Pickup, J. C., Williams, G., Eds.; Blackwell Scientific Publications: London, 1991; pp 462-476.
13. (b) Ferrannini, E. The Insulin Resistance Syndrome. Curr. Opin. Nephrol. Hypertens. 1992, 1, 291-298.
14. (a) The Diabetes Control and Complications Trials (DCCT). N. Engl. J. Med. 1993, 329, 683-689.
15. (b) American Diabetic Association. Diabetes 1993, 43, 1555-1558.
16. Steiner, K. E.; Lien, E. L. Hypoglycemic Agents which do not Release Insulin. In Progress in Medicinal Chemistry:, Ellis, G. P., West, C. B., Eds.; Elsevier: Oxford, 1987; Vol. 24, pp 209-248.
17. (a) Larson, E. R.; Clark, D. A.; Stevenson, R. W. New Approaches to Diabetes. Annu. Rep. Med. Chem. 1989, 25, 205-213.
18. (b) Colea, J. R.; Tanis, S. P. Recent advances in the discovery and development of potential antidiabetic agents. Annu. Rep. Med. Chem. 1992, 27, 219-226.
19. (c) Dow, R. L.; Kreutter, D. K. Recent Advancements in the Discovery and Development of Agents for the Treatment of Diabetes. Annu. Rep. Med. Chem. 1995, 30, 159-168.
20. (d) Hulin, B.; McCarthy, P. A.; Gibbs, E. M. The Glitazone Family of Antidiabetic Agents. Curr. Pharmacol. Des. 1996, 2, 85-102.
21. (e) Hulin, B. New Hypoglycemic Agents. Prog. Med. Chem. 1994, 31, 1-58.
22. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawanatsu, Y. Studies on Antidiabetic agents. II Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its derivatives. Chem. Pharm. Bull. 1982, 30, 3563-3573, 3580-3600.
23. (a) Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents X synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
24. (b) Meguro, K.; Fujita, T. EP 0155845, 1985; Chem. Abstr. 1986, 104, 186401a.
25. (b) Meguro, K.; Fujita, T. EP 0155845, 1985; Chem. Abstr. 1986, 104, 186401a.
26. (c) Sugiyama, Y.; Taketomi, S.; Shimara, Y.; Ikeda, H.; Fujita, T. Effects of Pioglitazone on Glucose and Lipid metabolism in Wistar fatty rats. Arzneim. Forsch. Drug Res. 1990, 40, 263-267.
27. (a) Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and analogous. 1. Hypolipidemic Agents with ability to Inhibit Lipid peroxidation. J. Med. Chem. 1989, 32, 421-428.
28. (b) Yoshioka, T.; Kotazata, E.; Yamazaki, M.; Hasegawa, K. Thiazolidinedione Derivatives, Their preparation and compositions containing them. EP 0139421, 1984; Chem. Abstr. 1985, 103, 540685.
29. (b) Yoshioka, T.; Kotazata, E.; Yamazaki, M.; Hasegawa, K. Thiazolidinedione Derivatives, Their preparation and compositions containing them. EP 0139421, 1984; Chem. Abstr. 1985, 103, 540685.
30. (a) Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones and Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
31. (b) Eggler, J. F.; Holland, G. F.; Johnson, M. R.; Volkmann, R. A. Hypoglyceamic Thiazolidinediones. U.S. Patent 4,738,972, 1985; Chem. Abstr. 1987, 107, 39794 q.
32. (b) Eggler, J. F.; Holland, G. F.; Johnson, M. R.; Volkmann, R. A. Hypoglyceamic Thiazolidinediones. U.S. Patent 4,738,972, 1985; Chem. Abstr. 1987, 107, 39794 q.
33. (c) Stevenson, R. W.; Hutson, N. J.; Krapp, M. N.; Volkmann, R. A.; Holland, G. F.; Eggler, J. F.; Clark, D. A.; McPherson, R. K.; Haell, K. L.; Danburg, B. H.; Gibbs, E. M.; Krentler, D. K Actions of Novel antidiabetic agents Englitazone in Hyperglycemic Hyperinsulinemic ob/ob mice. Diabetes 1990, 39, 1218-1227.
34. (a) Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The Synthesis of BRL-49653 - A Novel and Potent antihyperglycemic agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-1184.
35. (b) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [(ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 1994, 37, 3977-3985.
36. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamastsu, Y.; Iwatsuka, H.; Suzuoki, Z. Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(l-Methylcyclohexyl-methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878, U,63287, Ciglitazone), a New Antidiabetic Agent. Diabetes 1983, 32, 804-810.
37. (a) Williams, D. G.; Deldar, A.; Jordan, W. H.; Gries, C.; Long, G. G.; Dimarchi, R. D. Subchronic Toxicity of the Thiazolidinedione, Tanabe 174, in Rat and Dog. Diabetes 1993, 42 (Suppl 1), 59A (Abstr. 186).
38. (b) Deldar, A.; William, G.; Stevenes, C. Pathogenesis of Thiazolidinedione induced haemotoxocity in the dog. Diabetes 1993, 42 (Suppl. 1), 57A (Abstr. 179).
39. Troglitazone is being marketed in the United States as Rezulin and in Japan as Noscal.
40. (a) Kauramatsu, Y.; Fujita, T. Thiazolidine derivatives and pharmaceutical compositions comprising them. U.S. Patent 4 438 141; Chem. Abstr. 1980, 93, 114506v.
41. (a) Kauramatsu, Y.; Fujita, T. Thiazolidine derivatives and pharmaceutical compositions comprising them. U.S. Patent 4 438 141; Chem. Abstr. 1980, 93, 114506v.
42. (b) Kauramatsu, Y.; Fujita, T. Thiazolidine derivatives. U.S. Patent 4 461 902; Chem. Abstr. 1983, 99, 212516s.
43. (b) Kauramatsu, Y.; Fujita, T. Thiazolidine derivatives. U.S. Patent 4 461 902; Chem. Abstr. 1983, 99, 212516s.
44. (c) Meguro, K.; Fujita, T. 5-(4-Hydroxybenzyl)-2,4-dioxothiazolidine derivatives. U.S. Patent 4 775 687; Chem. Abstr. 1987, 106, 138436k.
45. (c) Meguro, K.; Fujita, T. 5-(4-Hydroxybenzyl)-2,4-dioxothiazolidine derivatives. U.S. Patent 4 775 687; Chem. Abstr. 1987, 106, 138436k.
46. (d) Krueger, B. W.; Huffman, H.; Roos, E.; Behrenz, W. Insecticidal Synergists. U.S. Patent 4 678 777; Chem. Abstr. 1986, 104, 22072z.
47. (d) Krueger, B. W.; Huffman, H.; Roos, E.; Behrenz, W. Insecticidal Synergists. U.S. Patent 4 678 777; Chem. Abstr. 1986, 104, 22072z.
48. (e) Meguro, K.; Fujita, T. Thiazolidinedione derivatives and their uses. U.S. Patent 4 725 610; Chem. Abstr. 1986, 105, 172446c.
49. (e) Meguro, K.; Fujita, T. Thiazolidinedione derivatives and their uses. U.S. Patent 4 725 610; Chem. Abstr. 1986, 105, 172446c.
50. (f) Meguro, K; Fujita, T. Thiazolidinedione derivatives and their medicinal compositions. U.S. Patent 4 582 839; Chem. Abstr. 1986, 104, 186401a.
51. (f) Meguro, K; Fujita, T. Thiazolidinedione derivatives and their medicinal compositions. U.S. Patent 4 582 839; Chem. Abstr. 1986, 104, 186401a.
52. (g) Meguro, K.; Fujita, T. Thiazolidine derivatives and their uses. U.S. Patent 4 687 777. Chem. Abstr. 1986, 105, 226543c.
53. (g) Meguro, K.; Fujita, T. Thiazolidine derivatives and their uses. U.S. Patent 4 687 777. Chem. Abstr. 1986, 105, 226543c.
54. (h) Eggler, J.; Holland, G. Thiazolidinedione derivatives as hypoglycemies and their preparations. Chem. Abstr. 1989, 110, 75483h.
55. (i) Clark, D. A. Preparation of (benzopyranyl-methyl)thiazolidinediones as hypoglycemic and anticholesteremic agents. U.S. Patent 4 791 125; Chem. Abstr. 1988, 111, 23503v.
56. (i) Clark, D. A. Preparation of (benzopyranyl-methyl)thiazolidinediones as hypoglycemic and anticholesteremic agents. U.S. Patent 4 791 125; Chem. Abstr. 1988, 111, 23503v.
57. (j) Clark, D. A.; Goldstein, S. W.; Hulin, B.; U.S. Patent 4 791 125, 1988.
58. (k) Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H. Characterization of New Oral Antidiabetic Agent CS-045. Diabetes 1988, 37, 1549-1558.
59. (l) Clark, D. A.; Goldstein, S. W.; Hulin, B. U.S. Patent 5 036 079.
60. (m) Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. J. Med. Chem. 1992, 35, 1853-1864.
61. (n) Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on Antidiabetic Agents. 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents. J. Med. Chem. 1992, 35, 2617-2626.
62. For Non-thiazolidinedione-like agents, see: Kees, K. L.; Cheeseman, R. S.; Prozialeck, D. H.; Steiner, K. E. Perfluoro-N-[4-(1Htetrazol-5-ylmethyl)phenyl]alkanamides. A New Class of Oral Antidiabetic Agents. J. Med. Chem. 1989, 32, 11-13.
63. For 2,4-oxazolidinediones, see: Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1544.
64. (a) Goldstein, S. W.; McDermott, R. E.; Gibbs, E. M.; Stevenson, R. W. Hydroxyurea Derivatives as Hypoglycemic Agents. J. Med. Chem. 1993, 36, 2238-2240.
65. (b) Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J., Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M., Jr.; Moore, R. D.; McCaleb, M. L. Studies on New Acidic Azoles as Glucose Lowering Agents in Obese, Diabetic db/db mice. J. Med. Chem. 1995, 38, 617-628.
66. (c) See ref 18b.
67. (d) See ref 18d.
68. (e) Yoshioka, T.; Kitazawa, E.; Kurumada, T.; Mitsuo, Y.; Hasegawa, K.; Fujita, T. Chroman thiazolidine derivatives as hypoglycemie agents and aldose reductase inhibitors and process for their preparation. EP 207 581, Chem. Abstr. 1987, 106, 119879r.
69. (f) See ref 18k.
70. (g) Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and Analogues. 1. Hypolipidemic and Hypoglycemic Agents with Ability to Inhibit Lipid Peroxidation. J. Med. Chem. 1989, 32, 421-428.
71. (h) Kees, K. L.; Cheeseman, R. S. Preparation of hypoglycemic 5-[[(hydroxyiminocyclohexyl)methoxy]benzyl ]-2,4-thiazolidinediones. U.S. Patent 4 728 739; Chem. Abstr. 1988, 109, 6505j.
72. (h) Kees, K. L.; Cheeseman, R. S. Preparation of hypoglycemic 5-[[(hydroxyiminocyclohexyl)methoxy]benzyl ]-2,4-thiazolidinediones. U.S. Patent 4 728 739; Chem. Abstr. 1988, 109, 6505j.
73. (i) Ijima, I.; Ozeka, M.; Okumura, K.; Inamasu, M. EP 283035-A, 1988; U.S. Patent 4 824 833.
74. (j) Cantello, B. C. C.; Hindley, R. M. Urea and thiourea derivatives of thiazolidinedione, a process for their preparation, their pharmaceutical compositions. EP 295 828a; Chem. Abstr. 1989, 110, 135231m.
75. (j) Cantello, B. C. C.; Hindley, R. M. Urea and thiourea derivatives of thiazolidinedione, a process for their preparation, their pharmaceutical compositions. EP 295 828a; Chem. Abstr. 1989, 110, 135231m.
76. (k) See ref 181.
77. (a) 56 Annual Meeting of American Diabetes Association, Moscone Centrera, San Francisco, CA, June 8-11, 1996.
78. (b) Insulin Resistance, Novel Drug Development Strategies for type-2 Diabetes and Obesity. International Business Communication, Oct. 31-Nov. 1, 1996.
79. (c) 57th Annual Meeting and Scientific Session, American Diabetes Association, Boston, MA, June 21-24, 1997.
80. 2 - Biochem. Biophys. Res. Commun. 1996, 224, 431-437.
81. Youngolale, G. A.; Sih, J. C.; Tanis, S. P.; Lin, C.-H. Preparation of α-amino indole-3-acetic acid useful as antidiabetic, antiobesity and antiatherosclerotic agents. WO 90 05721; Chem. Abstr. 1990, 113, 211831m.
82. Youngolale, G. A.; Sih, J. C.; Tanis, S. P.; Lin, C.-H. Preparation of α-amino indole-3-acetic acid useful as antidiabetic, antiobesity and antiatherosclerotic agents. WO 90 05721; Chem. Abstr. 1990, 113, 211831m.
83. Berlin, I.; Chalon, S.; Rosenzweig, P.; Fuseau, E.; Pueeh, A. J. Fundam. Clin. Pharmacol. 1993, 7, 348.
84. Berlin, I.; Rosenzweig, P.; Chalon, S.; Fuseau, E.; Landult, C.; Cesselin, F.; Blacker, C.; Puech, A. J. Clin. Pharmacol. Ther. 1994, 95, 338.
85. Lohray, B. B.; Bhushan, V.; Bheema Rao.T.; MadHavan, G.H.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Rajagopalan, R. Novel Thiazolidinedione Derivatives as Potent Euglycemic and Hypolipidemic Agents. Bioorg. Med. Chem. Lett. 1997, 7, 785-788.
86. Watt, S. D.; Profitt, J. A.; Corey, E. J. A Reagent for α,βReduction of conjugated Nitriles. J. Org. Chem. 1975, 40, 127-128.
87. Nate, H.; Matsuki, K.; Tsunashima, A.; Ohtsuka, H.; Sekine, Y. Synthesis of 2-phenylthiazolidine derivatives as cardiotonic agents. II. 2-(phenylpiperazinoalkoxyphenyl)thiazolidine-3-thiocarboxyamides and corresponding carboxy amides. Chem. Pharm. Bull. 1987, 35, 2394.
88. Horikoshi, H.; Yoshio, T.; Kawasaki, T.; Nakamura, K.; Matsumima, N.; Yamaguchi, K.; Sasahara, K. Troglitazone (CS-045), A New Antidiabetic Drug. Annu. Rep. Sankyo Res. Lab. 1994, 46, 1-57.
89. (a) Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by Peroxisome proliferator. Nature 1990, 347, 645-650.
90. (b) Clawla, A.; Schwarz, E. J.; Dimaculangan, D. D.; Lazar, M. A. Peroxisome proliferator activated receptor (PPARγ): adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135 (2), 798-800.
91. (c) Kilewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Manglesdorf, D. J.; Umesono, K.; Evans, R. M. Differential Expression and Activation of a family of Murine Peroxisome Proliferatory-activated Receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7355.
92. 2 is a ligand for the Adipocyte Determination Factor PPARθ, Cell 1995, 85, 803-812.
93. (b) Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, L D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The Structure Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the antihyperglycemic activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665.
94. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinediones as a High Affinity Ligands for Peroxisome ProliferatorActivated Receptor y (PPARy). J. Biol. Chem. 1995, 270, 12953-12956.
95. Flier, J. S. The Adipocyte Storage Depot or Node on the Energy Information Super highway. Cell 1995, 80, 15-18.
96. Calculation: The percent reduction was calculated according to the formula: 1 - [(TT/OT)/(TC/OC)] x 100, where TT, test day treated; OT, zero day treated; TC, test day control; OC, zero day control Statistics: All results are expressed as mean ± SE. The AUC was calculated according to trapezoidal rule. ANOVA was used for testing for significance between the control and treated groups. P value which is <0.05 is considered as significant.
97. Noland, W. E.; Baude, F. J. Organic Synthesis; John Wiley & Sons: New York, 1963; Collect. Vol. IV, p 567.
98. Noland, W. E.; Baude, F. J. Organic Synthesis; John Wiley & Sons: New York, 1963; Collect. Vol. IV, p 567.